While at the ASCO 2016 event, AstraZeneca emphasized the ongoing progress of its oncology pipeline, which is developing new treatments for patients who have cancer.
Nineteen of the 83 abstracts from ASCO were related to Lynparza and other new possible treatments. All of these treatments are designed to target the DNA damage that comes from having several different kinds of tumors.
One of the abstracts that will be presented is about durvalumab for bladder cancer. Others will discuss Breakthrough Therapy Designation; new information about Tagrisso passing through the blood-brain barrier for metastatic lung cancer patients; new insights for first-line NSCLC; and treating chronic lymphocytic leukemia with acalabrutinib.
“Oncology is a strategic priority for AstraZeneca because of the potential of our broad pipeline to offer transformational therapies in cancer care,” Sean Bohen, executive vice president of global medicines development at AstraZeneca, said. “At ASCO, we will update our next-generation portfolio, focusing on DNA damage response as a breakthrough paradigm in cancer treatment, including new long-term overall survival data for Lynparza. Our increased commitment to DDR therapies complements developments in our exciting immuno-oncology pipeline, from which we are expecting clinical results over the coming year.”
The goal of the conference is to give researchers a place where they can share different discoveries about oncology.
